NOME Investor Day – annual funding event

At this year’s NOME Investor Day at Hotel MJ’s in Malmö last week, 24 investors and 46 NOME companies engaged in one-to-one meetings. The event provided an excellent opportunity for NOME member companies to meet high-profile Nordic, European, and US life science investors to network, exchange insights, and lay the groundwork for future investments. Among the NOME member companies were Medicon Village members ApoGlyx, Asgard Therapeutics, and Colzyx.

Since its inception in 2016, the Nordic Mentor Network for Entrepreneurship (NOME) has supported life science start-ups, increasing their likelihood of success and strengthening the ecosystem. NOME is funded by the Novo Nordisk Foundation, with Medicon Village as one of 12 partner organisations representing the participating countries.

As a result of the programme’s success, in January 2024 the Novo Nordisk Foundation decided to increase funding and extend the programme through 2028, allowing NOME to expand into new geographies and industries. Over the past year, it has grown to cover not only the Nordics, but also the Baltics, northern Germany, and the UK, strengthening its role as a key player in the global life science industry.

More on NOME at https://www.mediconvillage.se/the-nordic-mentor-network-for-entrepreneurship-nome.